Cognitive Behavioral Therapy for Insomnia in People With Chronic Obstructive Pulmonary Disease(COPD)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2010 by University of Illinois.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Illinois
ClinicalTrials.gov Identifier:
NCT01072292
First received: February 18, 2010
Last updated: February 19, 2010
Last verified: February 2010
  Purpose

A two-phase research study is being conducted. In Phase 1 of the study, the cognitive behavioral therapy intervention for insomnia was implemented in a small (n = 5) group of people with moderate to severe COPD and insomnia. The intervention was pilot-tested to determine feasibility and acceptability, and the intervention will be refined as needed. In Phase 2 of the study, a two-group randomized controlled study (n = 20) will be conducted to test the effects of the cognitive behavioral therapy for insomnia intervention on the primary outcomes of sleep quality and fatigue and the secondary outcomes of mood and functional performance. It is hypothesized that people with COPD receiving cognitive behavioral therapy for insomnia will demonstrate significant improvements in sleep quality, fatigue, mood and functional performance as compared to people with COPD who receive a wellness program. This research will yield valuable information regarding effective interventions aimed at mitigating problems such as poor sleep quality, fatigue and reduced ability to perform valued daily activities. This information will be used to increase the likelihood of long-term successful outcomes such as the ability to maintain productive roles in society for people with COPD.


Condition Intervention
Insomnia
Behavioral: cognitive behavioral therapy for insomnia (CBT-I)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Nurse Managed Cognitive Behavioral Therapy for Insomnia in People With Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:


Further study details as provided by University of Illinois:

Primary Outcome Measures:
  • sleep quality [ Time Frame: 6-8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • fatigue/tiredness, using the Chronic Respiratory Disease Questionnaire [ Time Frame: 6-8 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 75
Study Start Date: June 2008
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: cognitive behavioral therapy for insomnia (CBT-I)
    CBT-I is a six week program designed to improve sleep quality in people with COPD.
  Eligibility

Ages Eligible for Study:   45 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects will have moderate to severe COPD. Severity of COPD will be defined according to the new GOLD standards (moderate IIA (moderate), 50% < FEV1 < 80% predicted; moderate IIB (severe) 30% < FEV1 < 50%). 58
  • Insomnia. Insomnia will be defined as difficulty initiating or maintaining sleep, waking up too early or poor quality sleep. 59
  • Subjects must be > 45 years of age with no other major health problems
  • Subjects must be clinically stable at the time of enrollment into the study without major exacerbation of COPD within the previous two months.

Exclusion Criteria:

  • Evidence of restrictive lung disease or asthma.
  • Evidence of a major sleep disorder other than insomnia (sleep apnea evidenced by apnea/hypopnea index of > 10, periodic limb movement disorder, narcolepsy).
  • Hypnotic, sedative, anxiolytic or antidepressant use.
  • Pulse oximetry (SaO2) reading of < 90% at rest.
  • Pulse oximetry (SaO2) reading of < 85% at night for > 5 minutes.
  • Significant sleep apnea (apnea/hypopnea index ≥ 10).
  • .Acute respiratory infection within the previous 2 months.
  • Class > 2 functional status according to the New York Heart Association.
  • The presence of a potentially debilitating disease such as cancer, congestive heart failure, kidney disease, liver failure or cirrhosis; evidence of alcohol or drug abuse, musculoskeletal or degenerative nerve disease.
  • A self-reported current diagnosis of major depression or psychiatric disease or a Hospital Anxiety and Depression Scale (HADS) depression score of > 11.
  • Currently participating in pulmonary rehabilitation.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01072292

Locations
United States, Illinois
University of Illinois at Chicago Recruiting
Chicago, Illinois, United States, 60612
Contact: Mary C Kapella, PhD     312-355-3150     mkapel1@uic.edu    
Principal Investigator: Mary C Kapella, PhD            
Sponsors and Collaborators
University of Illinois
  More Information

No publications provided

Responsible Party: Mary C. Kapella PhD, University of Illinois at Chicago
ClinicalTrials.gov Identifier: NCT01072292     History of Changes
Other Study ID Numbers: KO1 NR010749
Study First Received: February 18, 2010
Last Updated: February 19, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Sleep Initiation and Maintenance Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Disorders
Nervous System Diseases
Mental Disorders

ClinicalTrials.gov processed this record on May 21, 2013